Tevogen Inc.
TVGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001860871
No open-market purchases or sales by Tevogen Inc. insiders were filed in the last 90 days; 30 institutions reported holding it in 13F filings for Q2 2026, worth $607.7K in total; no superinvestor holds it.
Other share classesTVGNW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 30
- 13F valueReported value at the end of Q2 2026
- $607.7K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TVGN, Q2 2026
No superinvestor reported holding TVGN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Tevogen Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 (view filing) | Mar 10-13 | 7 daysLate | Flomenberg NealSee Remarks | SSale | −972 | $6.83 | −$6.64K | −1.2%76.9K after | 3 lots |
| Jun 9, 2025 (view filing) | Jun 9 | Same day | Saadi Ryan H.Chief Executive Officer | SSale | −1.44M | $1.23 | −$1.77M | −1.2%116.8M after | |
| Mar 14, 2025 (view filing) | Mar 12 | 2 days | Flomenberg NealSee Remarks | SSale | −233.0K | $1.09 | −$253.9K | −6.1%3.60M after | |
| Mar 11, 2025 (view filing) | Mar 7-11 | 4 days | Flomenberg NealSee Remarks | SSale | −211.9K | $1.09 | −$231.7K | −5.2%3.83M after | 3 lots |
| Mar 6, 2025 (view filing) | Mar 4-6 | 2 days | Flomenberg NealSee Remarks | SSale | −213.8K | $1.17 | −$250.0K | −5.0%4.04M after | 3 lots |
| Oct 18, 2024 (view filing) | Oct 17 | 1 day | Flomenberg NealSee Remarks | SSale | −1.08M | $1.62 | −$1.75M | −20.2%4.25M after | |
| Jun 13, 2024 (view filing) | Jun 12 | 1 day | Desai KirtiChief Financial Officer | PPurchase | +3.00K | $0.82 | +$2.46K | 0.0%9.70M after | |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Saadi Ryan H.Chief Executive Officer | PPurchase | +2.61K | $0.77 | +$2.01K | 0.0%118.3M after | |
| Jul 18, 2023 (view filing)5:36 PM ET | Jul 17 | 1 day | Corbin Capital Partners, L.P. and 2 others10% Owner | SSaleClass A Ordinary Shares, par value $0.0001 per share | −2.32M | $10.68 | −$24.8M | −100.0%0 after | 2 lots |
| Jun 8, 2023 (view filing) | Jun 7 | 1 day | Semper Paratus Sponsor LLC10% Owner | SSaleClass A Ordinary Shares, par value $0.0001 | −8.99M | $1.00 | −$8.99M | −67.7%4.29M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Tevogen Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 23,976 | $135.7K | 0.00% | −9,272−27.9% | Reduced |
| Morgan Stanley | 18,809 | $106.5K | 0.00% | +1,475+8.5% | Added |
| AQR Capital Management LLC | 17,237 | $97.6K | 0.00% | +17,237 | New |
| Goldman Sachs Group Inc | 14,163 | $80.2K | 0.00% | +14,163 | New |
| Jane Street Group, LLC | 11,175 | $63.3K | 0.00% | +11,175 | New |
| FMR LLC | 9,826 | $55.6K | 0.00% | −331−3.3% | Reduced |
| Russell Investments Group, Ltd. | 6,532 | $37.0K | 0.00% | +726+12.5% | Added |
| Tower Research Capital LLC (TRC) | 1,494 | $8.46K | 0.00% | +553+58.8% | Added |
| UBS Group AG | 1,083 | $6.13K | 0.00% | −2,484−69.6% | Reduced |
| Vanguard Fiduciary Trust Co | 838 | $4.74K | 0.00% | −530−38.7% | Reduced |